We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trevi Therapeutics Inc | NASDAQ:TRVI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -2.39% | 2.86 | 1.91 | 2.89 | 3.00 | 2.74 | 2.93 | 171,933 | 22:38:55 |
As filed with the Securities and Exchange Commission on July 6, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Trevi Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 45-0834299 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
|
195 Church Street, 14th Floor New Haven, Connecticut |
06510 | |
(Address of Principal Executive Offices) | (Zip Code) |
2019 Stock Incentive Plan
2019 Employee Stock Purchase Plan
(Full Title of the Plans)
Jennifer L. Good
President and Chief Executive Officer
Trevi Therapeutics, Inc.
195 Church Street, 14th Floor
New Haven, Connecticut 06510
(Name and Address of Agent For Service)
(203) 304-2499
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
|
||||||||
Title of Securities to be Registered |
Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed
Maximum
Offering Price |
Amount of
Registration Fee |
||||
Common Stock, $0.001 par value per share |
927,338(2) | $2.14(3) | $1,987,067.21(3) | $216.79 | ||||
|
||||||||
|
(1) |
In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) |
Consists of (i) 741,871 additional shares issuable under the 2019 Stock Incentive Plan, of which 85,463 are subject to outstanding stock options as of the date hereof, and (ii) 185,467 additional shares issuable under the 2019 Employee Stock Purchase Plan. |
(3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are based on (a) $2.17, the weighted average per share exercise price of the 85,463 shares subject to outstanding stock option grants under the 2019 Stock Incentive Plan as of the date hereof, at exercise prices ranging from $2.04 to $2.25 per share, and (b) for the remaining 656,408 shares issuable under the 2019 Stock Incentive Plan and the 185,467 shares issuable under the 2019 Employee Stock Purchase Plan, the average of the high and low prices of the Registrants Common Stock as reported on the Nasdaq Global Market on June 28, 2021. |
Statement of Incorporation by Reference
This Registration Statement on Form S-8, relating to the 2019 Stock Incentive Plan and the 2019 Employee Stock Purchase Plan of Trevi Therapeutics, Inc. (the Registrant), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference (i) the contents of the Registration Statement on Form S-8, File No. 333-231260, relating to the 2012 Stock Incentive Plan, as amended, of the Registrant, the 2019 Stock Incentive Plan of the Registrant (the 2019 Plan), and the 2019 Employee Stock Purchase Plan of the Registrant (the 2019 ESPP), filed by the Registrant with the Securities and Exchange Commission on May 7, 2019, and (ii) the contents of the Registration Statement on Form S-8, File No. 333-237193, relating to the 2019 Plan and the 2019 ESPP, filed by the Registrant with the Securities and Exchange Commission on March 16, 2020.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The following exhibits are incorporated herein by reference:
(1) |
Previously filed with the Securities and Exchange Commission on May 9, 2019 as an Exhibit to the Registrants Current Report on Form 8-K (File No. 001-38886) and incorporated herein by reference. |
(2) |
Previously filed with the Securities and Exchange Commission on April 5, 2019 as an Exhibit to the Registrants Registration Statement on Form S-1 (File No. 333-230745) and incorporated herein by reference. |
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New Haven, Connecticut, on this 6th day of July, 2021.
Trevi Therapeutics, Inc. | ||
By: |
/s/ Jennifer Good |
|
Jennifer Good | ||
President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Trevi Therapeutics, Inc., hereby severally constitute and appoint Jennifer Good and Christopher Galletta, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Trevi Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
/s/ Jennifer Good Jennifer Good |
President and Chief Executive Officer, Director (Principal executive officer and principal financial officer) | July 6, 2021 | ||
/s/ Christopher Galletta Christopher Galletta |
Controller (Principal accounting officer) | July 6, 2021 | ||
/s/ David Meeker, M.D. David Meeker, M.D. |
Chairman of the Board | July 6, 2021 | ||
/s/ James V. Cassella, Ph.D. James V. Cassella, Ph.D. |
Director | July 6, 2021 | ||
/s/ Dominick Colangelo Dominick Colangelo |
Director | July 6, 2021 |
/s/ Michael Heffernan Michael Heffernan |
Director | July 6, 2021 | ||
/s/ Edward Mathers Edward Mathers |
Director | July 6, 2021 | ||
/s/ Anne VanLent Anne VanLent |
Director | July 6, 2021 |
1 Year Trevi Therapeutics Chart |
1 Month Trevi Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions